JP6603662B2 - タンパク質のチオエーテルコンジュゲーション方法 - Google Patents

タンパク質のチオエーテルコンジュゲーション方法 Download PDF

Info

Publication number
JP6603662B2
JP6603662B2 JP2016538783A JP2016538783A JP6603662B2 JP 6603662 B2 JP6603662 B2 JP 6603662B2 JP 2016538783 A JP2016538783 A JP 2016538783A JP 2016538783 A JP2016538783 A JP 2016538783A JP 6603662 B2 JP6603662 B2 JP 6603662B2
Authority
JP
Japan
Prior art keywords
protein
conjugation
mixture
concentration
growth hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016538783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501148A (ja
JP2017501148A5 (enExample
Inventor
シャルロッテ・スコー・フネシェ
トーマス・ブッデ・ハンセン
エルンスト・ブロベルグ・ハンセン
Original Assignee
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴォ・ノルディスク・ヘルス・ケア・アーゲー filed Critical ノヴォ・ノルディスク・ヘルス・ケア・アーゲー
Publication of JP2017501148A publication Critical patent/JP2017501148A/ja
Publication of JP2017501148A5 publication Critical patent/JP2017501148A5/ja
Application granted granted Critical
Publication of JP6603662B2 publication Critical patent/JP6603662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016538783A 2013-12-13 2014-12-15 タンパク質のチオエーテルコンジュゲーション方法 Active JP6603662B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13197150 2013-12-13
EP13197150.9 2013-12-13
PCT/EP2014/077777 WO2015086853A1 (en) 2013-12-13 2014-12-15 Method for thioether conjugation of proteins

Publications (3)

Publication Number Publication Date
JP2017501148A JP2017501148A (ja) 2017-01-12
JP2017501148A5 JP2017501148A5 (enExample) 2018-01-25
JP6603662B2 true JP6603662B2 (ja) 2019-11-06

Family

ID=49765887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538783A Active JP6603662B2 (ja) 2013-12-13 2014-12-15 タンパク質のチオエーテルコンジュゲーション方法

Country Status (6)

Country Link
US (1) US11219690B2 (enExample)
EP (1) EP3079722B1 (enExample)
JP (1) JP6603662B2 (enExample)
CN (1) CN106068127B (enExample)
ES (1) ES2869309T3 (enExample)
WO (1) WO2015086853A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
BR112019024410A2 (pt) 2017-06-20 2020-07-14 Amgen Inc. método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
MX2019015544A (es) 2017-06-21 2020-07-28 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr).
JP7504025B2 (ja) * 2017-08-04 2024-06-21 アムジエン・インコーポレーテツド Ｃｙｓ－ｍａｂのコンジュゲーション方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042175A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
EP1012184B1 (en) 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2004101597A2 (en) 2003-05-13 2004-11-25 Frutarom Ltd. Methods for the reduction of disulfide bonds
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
US20090062509A1 (en) * 2006-03-16 2009-03-05 Aldo Cagnolini Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
US8586532B2 (en) 2007-08-24 2013-11-19 Novo Nordisk Healthcare A/G Method for selectively modifying a protein via transglutaminase catalyzed reaction
MX345736B (es) * 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
WO2011101261A2 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Purification method
CN103269720A (zh) 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
CA2836478A1 (en) 2011-05-27 2012-12-06 Baxter International Inc. Therapeutic protein conjugated to water-soluble polymers via reduced cysteine sulfhydryl group
TR201903707T4 (tr) * 2011-11-02 2019-04-22 Hoffmann La Roche Aşırı yükleme ve elüsyon kromatografisi.
CN103087183A (zh) * 2013-01-17 2013-05-08 南京邮电大学 一种光激发蛋白质中二硫键还原得到自由巯基的方法

Also Published As

Publication number Publication date
JP2017501148A (ja) 2017-01-12
ES2869309T3 (es) 2021-10-25
EP3079722A1 (en) 2016-10-19
US11219690B2 (en) 2022-01-11
CN106068127B (zh) 2020-06-19
WO2015086853A1 (en) 2015-06-18
EP3079722B1 (en) 2021-03-24
US20160303248A1 (en) 2016-10-20
CN106068127A (zh) 2016-11-02

Similar Documents

Publication Publication Date Title
JP6603662B2 (ja) タンパク質のチオエーテルコンジュゲーション方法
Liu et al. Precision conjugation: An emerging tool for generating protein–polymer conjugates
Zhang et al. Chromatographic separation of hemoglobin variants using robust molecularly imprinted polymers
Yan et al. Synthesis of peptides and proteins without cysteine residues by native chemical ligation combined with desulfurization
JP3659261B2 (ja) 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
FI113272B (fi) Parannettu proteiinien laskostamismenetelmä
Hackeng et al. Total chemical synthesis of human matrix Gla protein
US11345722B2 (en) High pH protein refolding methods
Annis et al. Novel Solid-Phase Reagents for Facile Formation of Intramolecular Disulfide Bridges in Peptides under Mild Conditions1, 2
MX2014010348A (es) Composiciones de conjugados de xten y métodos para realizarlas.
US11053278B2 (en) Tangential flow filtration based protein refolding methods
Sohma et al. Biomimetic synthesis of lispro insulin via a chemically synthesized “mini-proinsulin” prepared by oxime-forming ligation
Wong et al. Realizing serine/threonine ligation: scope and limitations and mechanistic implication thereof
Li et al. Methods for engineering therapeutic peptides
ES2532804T3 (es) Purificación de proteínas con tensioactivo catiónico
Gerling-Driessen et al. Exploiting Oligo (amido amine) backbones for the multivalent presentation of coiled-coil peptides
JP2017501148A5 (enExample)
Rahimizadeh et al. An albumin scaffold grafted with an alpha-helical motif delivers therapeutic payloads by modular coiled-coil assembly
Tallec et al. Adequate reducing conditions enable conjugation of oxidized peptides to polymers by one-pot thiol click chemistry
CN112679574B (zh) 一种基于青霉胺的多肽二硫键合成方法及其应用
JP5713006B2 (ja) チオスルホナート化合物、タンパク質及び／又はペプチドの可逆的カチオン化剤並びに可溶化方法
Kjeldsen et al. Dually reactive long recombinant linkers for bioconjugations as an alternative to PEG
Tom et al. Reproductible production of a PEGylated dual-acting peptide for diabetes
CN114891086B (zh) 一种生物素标记的gdf15的复性方法
CN120659799A (zh) 用于制备白蛋白溶液的方法及其用途和相关用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191011

R150 Certificate of patent or registration of utility model

Ref document number: 6603662

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250